Shots:

• Tyris to receive up front- research milestone along with research funding and will be responsible for generating clinical lead candidates and will further progress them to clinical development
• Almirall to get an exclusive option to acquire gene therapies and progress them through clinical development to commercialization
• The collaboration will integrate Tyris's non-viral based gene therapy technology and Almirall's expertise in medical dermatology. The alliance will focus on developing next-generation gene therapies with transformational potential for rare genetic dermatology diseases

 ­ Ref: PRNewswire | Image: Nature